

Promising clinical results from use of Episealer® accepted for presentation at the 35th AGA Congress in Austria

The presentation "*Patient-specific miniature surface replacement in refractory focal (osteo) chondral knee joint lesions of the middle-aged patient – 2 year results*" by Dr. Clemens Kösters from the Maria-Josef-Hospital, Greven, Germany has been accepted for the 35th AGA Congress, to be held in Linz, Austria in September 2018. The presentation will focus on 2-years' follow-up of surgeries performed in Germany with the Episealer® knee implant.

"Our patient population exceeding 24 months post-op is increasing and we are delighted with the fact that clinical results from the use of Episealer® knee implants will be presented at the AGA Congress. The AGA Congress is of great importance and this is a significant step for us in the Germany-Austria-Switzerland region" says Pål Ryfors, CEO of Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical's Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's µFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.